Merck and Moderna announced positive initial results from their first late-stage trial of an experimental personalized cancer vaccine combined with Merck's immunotherapy Keytruda. The phase three trial involving over 1,100 melanoma patients showed the combo significantly extended the time patients lived without cancer returning and reduced the risk of cancer spreading compared to Keytruda alone. The vaccine targets unique tumor mutations in each patient, offering a personalized approach. The companies plan to present the data at an upcoming medical meeting, with further study on overall survival ongoing, potentially leading to a new treatment option for melanoma and other cancers.
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
RoseNose Investing Group's Income Portfolio, yielding 5.6%, reached an all-time high value for the third time in July and is up 12.11% year-to-date. The portfolio includes 15 stocks flagged as overvalued due to their proximity to 52-week highs and lo...
